CSI Market
Sign In | Register

Generex Biotechnology (GNBT) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access GNBT Annual Income Statement →
By examining income statement figures across successive periods, users can identify shifts in Generex Biotechnology's profitability and expense structure.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Apr 30 2021)
Q3 2021 		(Jan 31 2021) (Oct 31 2020) (Jul 31 2020) (Apr 30 2020)
Revenues
Total Revenue0.02
Costs & Expenses
Cost of Goods and Services Sold0.07
Gross Profit-0.05
Selling, Administration, Marketing5.12
Depreciation & Amortization0.00
Research and Development Expense1.20
Restructuring, Accretion & Impairment Charges0.00
Other Operating Expense / -Income0.00
Total operating costs including COS6.38
Operating income / -loss-6.36
Interest Expense1.05
Net Interest Expense / -Income1.05
Other loss / -income-15.90
Total costs & expenses-8.46
Income & Taxes
Income / -loss before income taxes8.49
Income after income taxes8.49
Income / -loss from continuing operations8.49
Non-controlling interests-0.74
Net income / -loss8.49
Income / -loss to shareholder9.22
EBIT9.54
EBITD9.80
EBITDA10.45
Earnings Per Share
Basic EPS (excl. extra items)0.08
Basic Net EPS0.08
Basic shares outstanding (Mill. of Units)114.61
Diluted Net EPS-0.04
Diluted average shares (Mill. of Units)140.41
4 historic quarters locked

Sign in to unlock the full Generex Biotechnology income statement history.

Sign In Create Free Account

About GNBT Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.